Patents Assigned to Laboratorios Almirall, S.A.
  • Patent number: 8258308
    Abstract: The present disclosure relates to compounds of formula (I): or a pharmaceutically acceptable salt or N-oxide thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I), and to their methods of use in therapy.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: September 4, 2012
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Julio Cesar Castro Palomino Laria, Montserrat Erra Sola, Maria Estrella Lozoya Toribio, Eloisa Navarro Romero
  • Publication number: 20120115826
    Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
    Type: Application
    Filed: April 26, 2011
    Publication date: May 10, 2012
    Applicant: Laboratorios Almirall, S.A.
    Inventors: Carlos PUIG DURAN, Maria Isabel CRESPO CRESPO, Julio Cesar CASTRO PALOMINO LARIA, Silvia GUAL ROIG, Eloisa NAVARRO ROMERO
  • Publication number: 20120101075
    Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
    Type: Application
    Filed: April 26, 2011
    Publication date: April 26, 2012
    Applicant: Laboratorios Almirall, S.A.
    Inventors: Carlos PUIG DURAN, Maria Isabel CRESPO CRESPO, Julio Cesar CASTRO PALOMINO LARIA, Silvia GUAL ROIG, Eloisa NAVARROROMERO NAVARRO ROMERO
  • Patent number: 8044205
    Abstract: This present disclosure relates to a process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide by reacting 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R)yl ester and 3-phenoxypropyl bromide, wherein the reaction takes place in a solvent or mixtures of solvents having a boiling point from 50° C. to 210° C. and chosen from ketones and cyclic ethers.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: October 25, 2011
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Nuria Busquets Baque, Francesca Pajuelo Lorenzo
  • Patent number: 7906530
    Abstract: New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: March 15, 2011
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Juan Francisco Caturla Javaloyes, Laura Vidal Gispert, Wenceslao Lumeras Amador
  • Patent number: 7855202
    Abstract: The present disclosure relates to imidazopyridine derivatives of formula (I): The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2B adenosine receptor.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: December 21, 2010
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Bernat Vidal Juan, Silvia Fonquerna Pou, Paul Robert Eastwood, Jose Aiguade Bosch, Aranzazu Cardus Figueras, Ines Carranco Moruno, Jacob Gonzalez Rodriguez, Sergio Paredes Aparicio
  • Patent number: 7790728
    Abstract: The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R1 and R2 are chosen from a hydrogen atom and specified substituents, or b) R2, R1 and the —NH— group to which R1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2B adenosine receptor.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: September 7, 2010
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Bernat Vidal Juan, Christina Esteve Trias, Lidia Soca Pueyo, Paul Robert Eastwood
  • Publication number: 20100168161
    Abstract: The present relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I), and to their methods of use in therapy.
    Type: Application
    Filed: October 17, 2007
    Publication date: July 1, 2010
    Applicant: LABORATORIOS ALMIRALL, S.A.
    Inventors: Jordi Bach Tanã, Maria Isabel Crespo, Carlos Puig Duran, Silvia Gual Roig, Alberto Ortega Münoz
  • Patent number: 7718670
    Abstract: New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: May 18, 2010
    Assignee: Laboratorios Almirall S.A
    Inventor: Maria Prat Quinones
  • Publication number: 20100074898
    Abstract: The present disclosure relates to compounds of formula (I): or a pharmaceutically acceptable salt or N-oxide thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I), and to their methods of use in therapy.
    Type: Application
    Filed: December 21, 2007
    Publication date: March 25, 2010
    Applicant: LABORATORIOS ALMIRALL, S.A.
    Inventors: Julio Cesar Castro Palomino Laria, Montserrat Erra Sola, Maria Estrella Lozoya Toribio, Eloisa Navarro Romero
  • Patent number: 7662814
    Abstract: New 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives having the chemical structure of general formula (I), and pharmaceutically acceptable salts thereof are disclosed, as well as processes for their preparation and to pharmaceutical compositions containing them and their use in the treatment, prevention or suppression of pathological conditions, diseases and disorders susceptible of being improved by inhibition of PDE7.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: February 16, 2010
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Emma Terricabras Belart, Victor Manuel Segarra Matamoros, Julio Alvarez-Builla Gomez, Juan Jose Vaquero Lopez, Jose Miguel Minguez Ortega
  • Publication number: 20100012120
    Abstract: To provide an inhalation device which has improved use properties, particularly advanced moisture protection while in use, an inhalation device (1) for powder drugs is proposed comprising at least one storage chamber (13) for accommodating a plurality of drug powder doses and a dosing device which includes at least one dosing slider (15) which is movable approximately with a translatory movement in a dosing slider passage (16) at least from a filling position into an emptying position, wherein the inhalation device (1) further includes a device for inhalation-triggered automatic movement of the dosing slider (15) from its filling position into the emptying position and a return device for automatic movement of the dosing slider (15) back into the filling position.
    Type: Application
    Filed: December 21, 2007
    Publication date: January 21, 2010
    Applicant: LABORATORIOS ALMIRALL, S.A.
    Inventors: Martin Herder, Gerhard Ludanek, Ingo Mett
  • Patent number: 7622480
    Abstract: This invention is directed to selective antagonists of H1 histamine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: November 24, 2009
    Assignee: Laboratorios Almirall S.A.
    Inventors: Silvia Fonquerna Pou, Luis Miguel Pages Santacana, Carlos Puig Duran, Jose Manuel Prieto Soto, Aranzazu Cardus Figueras
  • Patent number: 7582676
    Abstract: The present invention relates to 2-phenylpyran-4-derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, and their medical uses.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: September 1, 2009
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Juan Francisco Caturla Javaloyes, Graham Warrellow
  • Patent number: 7560471
    Abstract: This invention is directed to new potent and selective antagonists of H1 histamine receptors having the general formula I to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy as antiallergic agents.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: July 14, 2009
    Assignee: Laboratorios Almirall S.A.
    Inventors: Silvia Fonquerna Pou, Luis Miguel Pages Santacana
  • Patent number: 7557212
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are provided as well as processes for the manufacture of such compounds. The compounds are useful in the treatment or prevention of inflammatory and allergic diseases.
    Type: Grant
    Filed: November 11, 2003
    Date of Patent: July 7, 2009
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Carlos Puig Duran, Daniel Perez Crespo, Jordi Bach Tana, Hamish Ryder
  • Publication number: 20090093503
    Abstract: A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receplors which is (3R)-1-phencthyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octanc, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.
    Type: Application
    Filed: December 16, 2008
    Publication date: April 9, 2009
    Applicant: Laboratorios Almirall, S.A.
    Inventors: Jordi Gras Escardo, Jesus Llenas Calvo, Hamish Ryder, Pio Orviz Diaz
  • Patent number: 7511038
    Abstract: New pyridazin-e-(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: March 31, 2009
    Assignee: Laboratorios Almirall S.A.
    Inventors: Vittorio Dal Piaz, Nuria Aguilar Izquierdo, Maria Antonia Buil Albero, Yolanda Garrido Rubio, Maria Paola Giovannoni, Jordi Gracia Ferrer, Wenceslao Lumeras Amador, Claudia Vergelli
  • Patent number: 7504398
    Abstract: This invention is directed to selective antagonists of A2A and/or A2B adenosine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: March 17, 2009
    Assignee: Laboratorios Almirall S.A.
    Inventors: Bernat Vidal Juan, Cristina Esteve Trias
  • Patent number: 7491722
    Abstract: Pyridazin-3(2H)-one derivatives of formula (I) are found to inhibit PDE-4. R1, R2 and R4 are organic radicals, R3 is a cyclic group, and R5 is an ester or an aryl or heteroaryl group.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: February 17, 2009
    Assignee: Laboratorios Almirall S.A.
    Inventors: Vittorio Dal Piaz, Nuria Aguilar Izquierdo, Maria Antonia Buil Albero, Marta Carrascal Riera, Jordi Gracia Ferrer, Maria Paola Giovannoni, Claudia Vergelli